Sheaff Brock Investment Advisors LLC Sells 15,431 Shares of Bristol-Myers Squibb (NYSE:BMY)

Sheaff Brock Investment Advisors LLC lessened its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,115 shares of the biopharmaceutical company's stock after selling 15,431 shares during the period. Sheaff Brock Investment Advisors LLC's holdings in Bristol-Myers Squibb were worth $1,647,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. AMF Tjanstepension AB grew its position in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company's stock valued at $31,618,000 after acquiring an additional 39,419 shares during the period. Swedbank AB lifted its position in Bristol-Myers Squibb by 0.9% during the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock valued at $162,440,000 after purchasing an additional 28,427 shares in the last quarter. Secure Asset Management LLC bought a new stake in Bristol-Myers Squibb during the third quarter valued at about $370,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Bristol-Myers Squibb by 2.9% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 261,388 shares of the biopharmaceutical company's stock worth $13,524,000 after buying an additional 7,340 shares in the last quarter. Finally, Trust Point Inc. raised its stake in shares of Bristol-Myers Squibb by 10.9% in the third quarter. Trust Point Inc. now owns 9,251 shares of the biopharmaceutical company's stock worth $479,000 after buying an additional 906 shares during the period. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Citigroup raised their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Bank of America reissued a "neutral" rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Jefferies Financial Group raised shares of Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Truist Financial lifted their price target on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Leerink Partners raised Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and boosted their target price for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of "Hold" and an average target price of $57.86.

Bristol-Myers Squibb Stock Up 0.0 %

Shares of Bristol-Myers Squibb stock traded up $0.02 during trading on Wednesday, hitting $54.45. 4,045,389 shares of the stock traded hands, compared to its average volume of 10,719,519. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock's fifty day simple moving average is $57.04 and its 200 day simple moving average is $54.23. The firm has a market cap of $110.49 billion, a P/E ratio of -12.32, a price-to-earnings-growth ratio of 2.00 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, equities analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 4.56%. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb's payout ratio is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.